[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905-602-5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2022, "totalPay": 79221, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "fiscalYear": 2022, "totalPay": 296616, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Diane  Gajewczyk", "title": "Vice President of Scientific & Medical Affairs", "fiscalYear": 2022, "totalPay": 241053, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.31, "open": 5.35, "dayLow": 5.32, "dayHigh": 5.47, "regularMarketPreviousClose": 5.31, "regularMarketOpen": 5.35, "regularMarketDayLow": 5.32, "regularMarketDayHigh": 5.47, "beta": 0.971, "trailingPE": 4.3015876, "forwardPE": 10.84, "volume": 6512, "regularMarketVolume": 6512, "averageVolume": 12505, "averageVolume10days": 21300, "averageDailyVolume10Day": 21300, "marketCap": 130200864, "fiftyTwoWeekLow": 2.2, "fiftyTwoWeekHigh": 5.77, "priceToSalesTrailing12Months": 6.155778, "fiftyDayAverage": 4.7354, "twoHundredDayAverage": 3.60255, "currency": "USD", "enterpriseValue": 85825616, "profitMargins": 1.5322701, "floatShares": 22592528, "sharesOutstanding": 24022300, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.44731998, "heldPercentInstitutions": 0.0101499995, "shortRatio": 0.97, "impliedSharesOutstanding": 24089800, "bookValue": 3.064, "priceToBook": 1.7689296, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "earningsQuarterlyGrowth": 1.649, "netIncomeToCommon": 32409000, "trailingEps": 1.26, "forwardEps": 0.5, "enterpriseToRevenue": 4.058, "enterpriseToEbitda": 7.328, "52WeekChange": 0.9032258, "SandP52WeekChange": 0.30279303, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CPHRF", "underlyingSymbol": "CPHRF", "shortName": "CIPHER PHARMACEUTICALS INC", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1138890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "33ee6a68-9bd5-3305-98c7-75445d99f34d", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.42, "recommendationKey": "none", "totalCash": 42086000, "totalCashPerShare": 1.752, "ebitda": 11712000, "totalDebt": 353000, "quickRatio": 3.833, "currentRatio": 4.066, "totalRevenue": 21151000, "debtToEquity": 0.455, "revenuePerShare": 0.839, "returnOnAssets": 0.08875, "returnOnEquity": 0.53132, "freeCashflow": 8199625, "operatingCashflow": 14798000, "earningsGrowth": 1.7, "revenueGrowth": 0.266, "grossMargins": 0.80851996, "ebitdaMargins": 0.55373, "operatingMargins": 0.49819002, "financialCurrency": "USD", "trailingPegRatio": null}]